BetaShares Global Healthcare ETF (ASX:DRUG) is a good way to invest in defensive shares

BetaShares Global Healthcare ETF (ASX: DRUG) is a good way to invest in a defensive global sector.

What BetaShares Global Healthcare ETF looks to do

The ETF aims to invest in a number of the world’s biggest healthcare businesses which can provide both defensive and growing earnings.

Looking at the portfolio, the top 10 holdings are: Johnson & Johnson, Roche Holding, UnitedHealth Group, Novartis, Merck & Co, Pfizer, Abbott Laboratories, Thermo Fisher Scientific, Eli Lilly and Co and Abbvie.

These businesses are some of the world’s biggest with very entrenched market positions. They specialise in different areas of the healthcare world. The biggest company – Johnson & Johnson – has a few different divisions: consumer health products, medical devices and pharmaceutical products. Many other of the large businesses have useful diversification within their businesses.

As you might expect, around two thirds of this ETF is invested in businesses listed in the US. Then 11.5% is allocated to Swiss healthcare shares, 6.9% is allocated to Japan shares, 5.4% is allocated to UK shares, 3.1% is allocated to French shares,

Fees

BetaShares Global Healthcare ETF has a fairly low cost for how much geographical diversification you get with it. The annual operating cost is just 0.57% per year. Plenty of active Australian fund managers charge annual management fees of 1% per annum.

There are ETFs out there with much lower fees like Vanguard U.S. Total Market Shares Index ETF (ASX: VTS) which has a management fee of just 0.03% per year. So you need to decide if that extra 0.54% per annum is worth getting the specific exposure to these healthcare giants.

ETF performance

BetaShares Global Healthcare ETF isn’t necessarily going to shoot the lights out over the short term or long term. But I think its returns have been reliable. Over the past three years it has returned, after fees, an average of 10.27% per year.

That’s better than the ASX but not as good as ETFs that are invested across every industry. As an Aussie, I’d rather go for something like iShares S&P 500 ETF (ASX: IVV) for my international diversification.

From 200+ ETFs in Australia, our top investment analyst has just identified his #1 ETF for 2021 and beyond.

Low fees? Check.

Long-term growth potential? Check.

Regular cash returns? Check!

This ETF makes investing in ETFs "Super-Easy".

Simply click here or enter your email address below to access the full ETF report, ticker code, and step-by-step investment guide. Our expert's #1 ETF report is completely free.

No gimmicks, no payment, no credit card info. Just enter your email address below and we'll send you the report right away.

From 200+ ETFs in Australia, our top investment analyst has just identified his #1 ETF for 2021 and beyond.

Low fees? Check.

Long-term growth potential? Check.

Regular cash returns? Check!

This ETF makes investing in ETFs "Super-Easy".

Simply click here to access the full ETF report, ticker code, and step-by-step investment guide. Our expert's #1 ETF report is completely free.

No gimmicks, no payment, no credit card info. Just click the link below and enter your email address. We'll send you the report right away.

CLICK HERE TO GET THE REPORT

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Keep reading:

General Financial Advice warning
The information on this website is general financial advice only. That means, the advice does not take into account your objectives, financial situation or needs. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. Please read our Terms & Conditions and Financial Services Guide before using this website.

© Rask Australia 2020

Join 20,000+ smart investors

Join the Rask Australia mailing and we’ll send you free investment reports, podcasts, expert insights, investing courses, ASX news and lots, lots more. All free. 

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian-owned.

feedback-icon

What can we do better? Please give us us some feedback :)

We care about your experience, please let us know if you have any suggestions to improve our site.